Therapeutic use of convalescent plasma in COVID-19 patients with immunodeficiency: A systematic review

In the absence of effective countermeasures, human convalescent plasma has been widely used to treat severe acute respiratory syndrome coronavirus 2 including among patients with innate or acquired immunodeficiency. However, the association between COVID-19-associated mortality in patients with immunodeficiency and therapeutic use of convalescent plasma is unknown. We review clinical features and treatment protocols of COVID-19 patients with immunodeficiency after treatment with human convalescent plasma. We also discuss the time course and clinical features of recovery. These insights provide evidence for the need to develop a clear treatment protocol for COVID-19 patients with immunodeficiency and support the efficacy of convalescent plasma in patients with primary or secondary immunodeficiency.

[1]  M. Addo,et al.  Sustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  T. Bhatnagar,et al.  Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) , 2020, BMJ.

[3]  F. Simeone,et al.  Safety and efficacy of COVID‐19 convalescent plasma in severe pulmonary disease: A report of 17 patients , 2020, Transfusion medicine.

[4]  G. Pugliese,et al.  Severe COVID-19 in Third Trimester Pregnancy: Multidisciplinary Approach , 2020, Case reports in critical care.

[5]  Arvind Singh Tomar,et al.  COVID-19 in Liver Transplant Recipients - A Series with Successful Recovery , 2020, Journal of clinical and translational hepatology.

[6]  T. Luetkens,et al.  Successful transfer of anti–SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19 , 2020, Blood Advances.

[7]  M. Graham,et al.  Bronchoalveolar lavage-based COVID-19 testing in patients with cancer , 2020, Hematology/Oncology and Stem Cell Therapy.

[8]  R. Olsen,et al.  Early transfusion of a large cohort of COVID-19 patients with high titer anti-SARS-CoV-2 spike protein IgG convalescent plasma confirms a signal of significantly decreased mortality , 2020, medRxiv.

[9]  Booth Wainscoat,et al.  A 63-Year-Old Woman with a History of Non-Hodgkin Lymphoma with Persistent SARS-CoV-2 Infection Who Was Seronegative and Treated with Convalescent Plasma , 2020, The American journal of case reports.

[10]  J. Mascarenhas,et al.  Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia , 2020, Journal of Hematology & Oncology.

[11]  R. Carter,et al.  In Reply — Limitations of Safety Update on Convalescent Plasma Transfusion in COVID-19 Patients , 2020, Mayo Clinic Proceedings.

[12]  W. Geng,et al.  Convalescent Plasma Rescued a Severe COVID-19 Patient with Chronic Myeloid Leukemia Blast Crisis and Myelofibrosis. , 2020, Turkish journal of haematology : official journal of Turkish Society of Haematology.

[13]  D. Yokoe,et al.  Treatment of immunocompromised COVID‐19 patients with convalescent plasma , 2020, Transplant infectious disease : an official journal of the Transplantation Society.

[14]  H. Trimarchi,et al.  Eculizumab, SARS-CoV-2 and atypical hemolytic uremic syndrome , 2020, Clinical kidney journal.

[15]  N. Radhakrishnan,et al.  Convalescent plasma to aid in recovery of COVID-19 pneumonia in a child with acute lymphoblastic leukemia , 2020, Transfusion and Apheresis Science.

[16]  B. Lambrecht,et al.  Coronavirus disease 2019 in patients with inborn errors of immunity: An international study , 2020, Journal of Allergy and Clinical Immunology.

[17]  C. Wobus,et al.  Prolonged SARS-CoV-2 replication in an immunocompromised patient , 2020, medRxiv.

[18]  P. Gallian,et al.  Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19 , 2020, Blood.

[19]  Nicole M. Bouvier,et al.  Convalescent Plasma for the Treatment of Severe COVID‐19 Infection in Cancer Patients , 2020, Cancer Medicine.

[20]  C. Cordon-Cardo,et al.  Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma , 2020, The Journal of Allergy and Clinical Immunology: In Practice.

[21]  Nicole M. Bouvier,et al.  Treatment with convalescent plasma in solid organ transplant recipients with COVID‐19: Experience at large transplant center in New York City , 2020, Clinical transplantation.

[22]  S. Stowell,et al.  COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease , 2020, Blood Advances.

[23]  K. Sullivan,et al.  Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome , 2020, Pediatric blood & cancer.

[24]  Z. Kashi,et al.  Coronavirus Disease 2019 Viremia, Serologies, and Clinical Course in a Case Series of Transplant Recipients , 2020, Transplantation Proceedings.

[25]  J. Bailey,et al.  Successful recovery from COVID‐19 in three kidney transplant recipients who received convalescent plasma therapy , 2020, Transplant infectious disease : an official journal of the Transplantation Society.

[26]  E. Aksoy,et al.  COVID-19 Presentation in Association with Myasthenia Gravis: A Case Report and Review of the Literature , 2020, Case reports in infectious diseases.

[27]  A. Casadevall,et al.  Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience , 2020, medRxiv.

[28]  E. Bloch.  Convalescent plasma to treat COVID-19 , 2020, Blood.

[29]  A. Saburi,et al.  Convalescent plasma therapy in a pregnant COVID-19 patient with a dramatic clinical and imaging response: A case report , 2020, World journal of radiology.

[30]  M. Salesi,et al.  Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study , 2020, Transfusion and Apheresis Science.

[31]  C. Ortega,et al.  Rapid recovery of a SARS-CoV-2–infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma , 2020, The Journal of Allergy and Clinical Immunology: In Practice.

[32]  S. Aksu,et al.  Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma , 2020, Transfusion and Apheresis Science.

[33]  M. M. van der Eerden,et al.  Convalescent Plasma for COVID-19. A randomized clinical trial , 2020, medRxiv.

[34]  P. Zhou,et al.  Convalescent plasma therapy: Helpful treatment of COVID‐19 in a kidney transplant recipient presenting with severe clinical manifestations and complex complications , 2020, Clinical transplantation.

[35]  G. Cartron,et al.  Convalescent plasma for persisting COVID‐19 following therapeutic lymphocyte depletion: a report of rapid recovery , 2020, British journal of haematology.

[36]  A. Cap,et al.  Successful Use of COVID-19 Convalescent Plasma in a Patient Recently Treated for Follicular Lymphoma , 2020, Clinical Lymphoma Myeloma and Leukemia.

[37]  Alex K. Williamson,et al.  COVID‐19 in recent heart transplant recipients: Clinicopathologic features and early outcomes , 2020, Transplant infectious disease : an official journal of the Transplantation Society.

[38]  A. Hess,et al.  Hospitalized COVID-19 patients treated with Convalescent Plasma in a mid-size city in the midwest , 2020, medRxiv.

[39]  N. Saba,et al.  COVID-19 in allogeneic stem cell transplant: high false-negative probability and role of CRISPR and convalescent plasma , 2020, Bone Marrow Transplantation.

[40]  M. Brodmann,et al.  Response to “COVID-19 in persons with haematological cancers” , 2020, Leukemia.

[41]  S. Jagannath,et al.  A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward , 2020, medRxiv.

[42]  L. Ren,et al.  Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. , 2020, JAMA.

[43]  S. Aksu,et al.  Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis , 2020, Transfusion and Apheresis Science.

[44]  T. Lv,et al.  Treatment with convalescent plasma for COVID‐19 patients in Wuhan, China , 2020, Journal of medical virology.

[45]  Wayne T. Nicholson,et al.  Deployment of convalescent plasma for the prevention and treatment of COVID-19. , 2020, The Journal of clinical investigation.

[46]  He Huang,et al.  Mechanisms and rejuvenation strategies for aged hematopoietic stem cells , 2020, Journal of Hematology & Oncology.

[47]  Arturo Casadevall,et al.  The convalescent sera option for containing COVID-19. , 2020, The Journal of clinical investigation.

[48]  Smita Y. Patel,et al.  The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management , 2019, Front. Immunol..

[49]  E. Gelfand,et al.  Common Variable Immunodeficiency: Diagnosis, Management, and Treatment. , 2015, Immunology and allergy clinics of North America.

[50]  Kwok-Hung Chan,et al.  Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus Infection , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[51]  S. Hoffman,et al.  Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment? , 2006, Annals of Internal Medicine.

[52]  P. Chan,et al.  Use of convalescent plasma therapy in SARS patients in Hong Kong , 2004, European Journal of Clinical Microbiology and Infectious Diseases.